Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.25100/cm.v51i4.4613 http://scihub22266oqcxt.onion/10.25100/cm.v51i4.4613 33795896!7968425!33795896     free     free     free Warning: file_get_contents(https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&id=33795896&cmd=llinks): Failed to open stream: HTTP request failed! HTTP/1.1 429 Too Many Requests in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 215       Colomb+Med+(Cali) 2020 ; 51 (4): e2014613 Nephropedia Template TP {{tp|p=33795896|t=2020. COVID-19: The Ivermectin African Enigma |pdf=|usr=}}{{33795896}} gab.com Text COVID-19: The Ivermectin African Enigma JO: Colomb Med (Cali) http://www.kidney.de/pget.php?&tw=1&pmid=33795896 #FOAvip INTRODUCTION: The low frequency of cases and deaths from the SARS-CoV-2 COVID-19 virus in some countries of Africa has called our attention about the unusual behavior of this disease. The ivermectin is considered a drug of choice for various parasitic and viral diseases and shown to have in vitro effects against SARS-CoV-2. AIMS: Our study aimed to describe SARS-CoV2 infection and death rates in African countries that participated in an intensive Ivermectin mass campaign carried out to control onchocerciasis and compare them with those of countries that did not participate. METHODS: Data from 19 countries that participated in the World Health Organization (WHO) sponsored African Programme for Onchocerciasis Control (APOC), from 1995 until 2015, were compared with thirty-five (Non-APOC), countries that were not included. Information was obtained from https://www.worldometers.info/coronavirus/ database. Generalized Poisson regression models were used to obtain estimates of the effect of APOC status on cumulative SARS-CoV-2 infection and mortality rates. RESULTS: After controlling for different factors, including the Human Development Index (HDI), APOC countries (vs. non-APOC), show 28% lower mortality (0.72; 95% CI: 0.67-0.78) and 8% lower rate of infection (0.92; 95% CI: 0.91-0.93) due to COVID-19. CONCLUSIONS: The incidence in mortality rates and number of cases is significantly lower among the APOC countries compared to non-APOC countries. That a mass public health preventive campaign against COVID-19 may have taken place, inadvertently, in some African countries with massive community ivermectin use is an attractive hypothesis. Additional studies are needed to confirm it. Twit Text FOAVip COVID-19: The Ivermectin African Enigma ????Colomb Med (Cali) http://www.kidney.de/pget.php?&tw=1&pmid=33795896 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=33795896 #FOAvip English Wikipedia <ref>{{Cite pmid|33795896}}</ref> COVID-19: The Ivermectin African Enigma #MMPMID33795896 Guerrero R; Bravo LE; Munoz E; Ardila EKG; Guerrero E Colomb Med (Cali) 2020[Dec]; 51 (4): e2014613 PMID33795896show ga INTRODUCTION: The low frequency of cases and deaths from the SARS-CoV-2 COVID-19 virus in some countries of Africa has called our attention about the unusual behavior of this disease. The ivermectin is considered a drug of choice for various parasitic and viral diseases and shown to have in vitro effects against SARS-CoV-2. AIMS: Our study aimed to describe SARS-CoV2 infection and death rates in African countries that participated in an intensive Ivermectin mass campaign carried out to control onchocerciasis and compare them with those of countries that did not participate. METHODS: Data from 19 countries that participated in the World Health Organization (WHO) sponsored African Programme for Onchocerciasis Control (APOC), from 1995 until 2015, were compared with thirty-five (Non-APOC), countries that were not included. Information was obtained from https://www.worldometers.info/coronavirus/ database. Generalized Poisson regression models were used to obtain estimates of the effect of APOC status on cumulative SARS-CoV-2 infection and mortality rates. RESULTS: After controlling for different factors, including the Human Development Index (HDI), APOC countries (vs. non-APOC), show 28% lower mortality (0.72; 95% CI: 0.67-0.78) and 8% lower rate of infection (0.92; 95% CI: 0.91-0.93) due to COVID-19. CONCLUSIONS: The incidence in mortality rates and number of cases is significantly lower among the APOC countries compared to non-APOC countries. That a mass public health preventive campaign against COVID-19 may have taken place, inadvertently, in some African countries with massive community ivermectin use is an attractive hypothesis. Additional studies are needed to confirm it. |Africa/epidemiology[MESH] |Antiparasitic Agents/*therapeutic use[MESH] |COVID-19/*epidemiology/mortality/*prevention & control[MESH] |Humans[MESH] |Ivermectin/*therapeutic use[MESH]COVID-19: The Ivermectin African Enigma (epmc).pdf DeepDyve Pubget Overpricing